Epcoritamab

CAS No. 2134641-34-0

Epcoritamab( —— )

Catalog No. M37173 CAS No. 2134641-34-0

Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1311 In Stock
10MG 2138 In Stock
25MG 3183 In Stock
50MG 4204 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Epcoritamab
  • Note
    Research use only, not for human use.
  • Brief Description
    Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.
  • Description
    Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2134641-34-0
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. van der Horst HJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021 Feb 18;11(2):38. ?
molnova catalog
related products